期刊文献+

正常健康人群外周血液中OPG和sRANKL浓度测定 被引量:5

Concentration measurement of the OPG and sRANKL of peripheral blood among normal healthy people
下载PDF
导出
摘要 目的:对正常健康人群外周血液中骨保护素(Osteoprotegerin,OPG)、核因子kappaB受体活化因子配体(receptor activator of NFκBligand,RANKL)浓度测定,明确其与年龄、性别之间是否存在一定关系。方法:收集220例正常健康人的清晨外周血液,其中男108例,女112例;年龄35~70岁,平均52.5岁。用ELISA法测血清中OPG、sRANKL浓度。结果:在35~70岁正常健康人群外周血液中的OPG、sRANKL浓度:女性,OPG21.95~315.47pg/ml,sRANKL10.25~370.20pmol/L;男性,OPG14.78~192.55pg/ml,sRANKL9.25~300.32pmol/L。46岁后女性血液中OPG浓度与年龄存在正相关;57岁后女性血液中sRANKL浓度明显升高。结论:年龄和性别影响外周血液中OPG、sRANKL浓度。46岁后女性血液中OPG浓度随年龄增加而升高,女性血液中sRANKL浓度57岁后明显升高。 Objective:To measure the concentration of osteoprotegerin (OPG) and receptor activator of NF κB ligand (sRANKL) in peripheral blood among normal healthy people and investigate the relationship pf the concentration with age and sex. Methods:The peripheral blood samples of 220 normal healthy people (included 108 males and 112 females,aged from 35 to 70) were collected in the morning. The OPG and sRANKL concentration of blood serum were measured by ELISA. Results: The concentrations in female peripheral blood were:OPG 21.95 to 315.47 pg / ml,sRANKL 10.25 to 370.20 pmol / L;while in male were:OPG 14.78 to 192.55 pg / ml,sRANKL 9.22 to 300.32 pmol / L. There was positive correlation between the OPG concentration and age in the females older than 46 years. And for female older than 57,the sRANKL concentration of peripheral blood increases obviously. Conclusion:Age and sex are the elements that affect the OPG and sRANKL concentration in peripheral blood. For female older than 46,the OPG concentration of peripheral blood increases with age,while the sRANKL concentration of peripheral blood increases for females older than 57.
出处 《中国骨伤》 CAS 2010年第2期87-89,共3页 China Journal of Orthopaedics and Traumatology
基金 全军"十一五"重点攻关项目基金(编号:06G043)
关键词 骨保护素 核激活因子受体配体 浓度测定 外周血 健康人 Osteoprotegerin (OPG) Receptor activator of nuclear factor κB ligand (RANKL) Concentration measurement Peripheral blood Healthy people
  • 相关文献

参考文献8

  • 1王扬天,王坚,马驰原.核因子-κB与糖尿病的关系[J].医学研究生学报,2007,20(3):310-314. 被引量:15
  • 2Sobacchi C, Frattini A, Guerrini MM, et al. Osteoclast-poor human osteopetrosis due to mutations in the gene encoding RANKL. Nat Genet, 2007,39 : 960-962.
  • 3Hannon R,Eastell R. Preanalytical variability of biochemical markers of bone turnover. Osteoporos Int,2000, 11 (Suppl 6) :30-44.
  • 4陈柏龄,谢登辉,王宗伟,李佛保,徐栋梁,黎艺强.淫羊藿总黄酮对去卵巢大鼠骨组织OPG、OPGLmRNA表达的影响[J].中国骨伤,2009,22(4):271-273. 被引量:40
  • 5Chan BY ,Buckley KA,Durham BH,et al. Effect of anticoagulants and storage temperature on the stability of receptor activator for nuclear factor-kappaB ligand and osteoprotegerin in plasma and serum. Clin Chem, 2003,49 (12) : 2083-2085.
  • 6Rogers A,Saleh G, Hannon RA ,et al. Circulating estradiol and osteoprotegerin as determinants of bone turnover and bone density in postmenopausal women. J Clin Endocrinology Metabolism, 2002,87 ( 10 ) : 4470-4475.
  • 7Trofimov S,Pantsulaia Ia,Eugene Kobyliansky,et al. Circulating levels of receptor activator of nuclear factor-kappaB ligand/nsteoprotegerin/macrophage-colony stimulating factor in a presumably healthy human population. Eur J Endocrinol, 2004,150 : 305-311.
  • 8Rogers A,Eastell R. Circulating osteoprotegerin and receptor activator for nuclear factor-kappaB ligand:clinical utility in metabolic bone disease assessment. J Clin Endocrinol Metabol,2005,90 ( 11 ) :6323-6331.

二级参考文献32

  • 1狄红杰,赵明,王扬天.糖尿病大鼠视网膜病变核因子-κB表达水平的研究[J].医学研究生学报,2006,19(4):341-343. 被引量:8
  • 2王扬天,赵明,狄红杰.糖尿病大鼠肾病变过程中核因子-κB及诱导型一氧化氮合酶的表达[J].医学研究生学报,2006,19(5):416-419. 被引量:6
  • 3Loser K,Mehling A,Loeser S,et al. Epidermal RANKL controls regulatory T-cell numbers via activation of dendritic cells. Nat Med, 2006,12(12) : 1372-1379.
  • 4Mueller RJ, Richards RG. Immunohistological identification of receptor activator of NF-kappaB ligand (RANKL) in human,ovine and bovine bone tissues, j Mater Sci Mater Med, 2004,15 (4) :367- 372.
  • 5Theoleyre S,Wittrant Y,Couillaud S,et al. Cellular activity and signaling induced by osteoprotegerin in osteoclasts:involvement of receptor activator of nuclear factork B ligand and MAPK. Biochim Biophys Acta ,2004,1644 ( 1 ) : 1-7.
  • 6Wittrant Y,Theoleyre S, Couillaud S,et al. Relevance of an in vitro osteoclastogenesis system to study receptor activator of NF-kB ligand and osteoprotegerin biological activities. Exp Cell Res, 2004, 293(2) :292-301.
  • 7Sen R,Baltimore D.Multiple nuclear factors interact with the immunoglobulin enhancer sequence[J].Cell,1986,46(5):705-716.
  • 8Andrew B,Luke AJ.Oxidative stress and nuclear factor-κB activation[J].Biol Pharmacol,2000,59(1):12-23.
  • 9Goebeler M,Gillitzer R,Kilian K,et al.Multiple signaling pathways regulates NF-kappa B-dependent transcription of the monocyte chemoattractant protein-1 gene in primary endothelial cell[J].Blood,2001,97(1):46-55.
  • 10Dandona P,Aljada A,Chaudhuri A,et al.Metabolic syndrome:a comprehensive perspective based on interactions between obesity,diabetes,and inflammation[J].Circulation,2005,111(11):1448-1454.

共引文献53

同被引文献71

  • 1Sasaki N, Kusano E. Bone and bone related biochemical ex- aminations. Bone and collagen related metabolites, Measure- ment and clinical rule of OPG. Clin Calcium, 2006,16 (6) : 956 - 962.
  • 2Asuda H. Bone and bone related biochemical examinations. Bone anti - collagen related metabolites. Receptor activator of NF - kappaB ligand (RANKL). Clin Calcium, 2006,16 (6) :964 - 970.
  • 3Zhang Y H, Heulsmann A,Tondravi MM, et al. Tumor necro- sis factor - alpha ( TNF ) stimulates RANKL induced oste- oclastogenesis Via coupling of TNF type I receptor and RANK signaling pathways. J Bid Chem, 2001,276 ( 1 ) : 563 -568.
  • 4Haynes DR, Crotti TN, Potter AE, et al, The osteoclastogenic molecules RANKL and RANK are associated with peripros- thetic osteolysis. J Bone Joint Surg(Br) ,2001,83 -B :902 - 911.
  • 5Itonaga I,Sabokbar A,Murray DW,et al. Effect of osteopro-tegerin and osteoprotegerin ligand on osteoclast formation by arthroplasty membrane derived maerophages. Ann Rheum Dis,2000,59( 1 ) :26 - 31.
  • 6Masui T, Sakano S, Hasegawa Y,et al. Expression of inflama- tory cytokines, RANKL and OPG induced by titanium , co- baltchronium and polyethylene particles. Biomaterials, 2005, 26(14) :1695 - 1702.
  • 7Von Knoch F, Heckelei A, Wedemeyer C, etal. Suppression of polyethylene particle - induced osteolysis by exogenous os- teoprotegerin. J Biomed Mater Res,2005,75 (2) :288 - 294.
  • 8Granchi D, Pellacani A, Spina M, et al. Serum levels of os- teoprotegerin and receptor activator of nuclear factor - kap- paB ligand as makers of periprosthefic osteolysis. J Bone Joint Surg Am,2006,88(7) :1501 - 1519.
  • 9Lacey D,Timms E,Tan H,et al. Osteoprotegerin ligand is a cy- tokine that regulates osteoclast differentiation and activation [J]. Cell, 1998,93 (2) : 165-176.
  • 10Simonet W, Lacey D, Dunstan C, et al. Osteoprotegerin : a novel se- creted protein involved in the regulation of bone density[J]. Cell, 1997,89(2) :309-319.

引证文献5

二级引证文献59

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部